• Je něco špatně v tomto záznamu ?

One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge

N. Majtanova, A. Takacova, V. Kurilova, L. Hejsek, J. Majtan, P. Kolar

. 2025 ; 14 (1) : 153-167. [pub] 20241122

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25001886

INTRODUCTION: This study was performed to compare the efficacy and safety of PreserFlo MicroShunt (PMS) implantation with mitomycin C (MMC) applied by sub-tenon injection versus conventional application by MMC-soaked sponges. METHODS: This retrospective, 1-year cohort study included 100 eyes of 100 patients with glaucoma who underwent PMS implantation with MMC (0.4 mg/ml) delivered either by sub-tenon injection (50 eyes) or via soaked sponges (50 eyes). The primary outcome measure at 1 year was intraocular pressure (IOP) reduction, with complete success defined as an IOP reduction of ≥ 20% and achieving a target IOP of ≤ 21 or 18 mmHg without the use of medication. Secondary outcomes, including corneal endothelial cell density (CECD) loss, the number of medications, and complications, were assessed and compared between the groups. RESULTS: Sustained reductions in mean IOP were observed in both groups over the 1-year follow-up, with no significant differences between the groups. The complete success rate, with a target IOP of ≤ 21 mmHg after 1 year, was 19.3% in the sponge group and 26.4% in the injection group. The qualified success rate was 59.0% and 87.4% in the sponge and injection groups, respectively. A longer survival rate was observed in the injection group than in the sponge group when IOP was below 21 mmHg. The mean CECD significantly decreased (P < 0.01) from baseline to each postoperative follow-up time point in both groups. At 1 year postoperatively, the percentage of total CECD loss was 8.1% in the sponge group and 8.0% in the injection group. However, no significant differences in mean CECD values, the number of medications, or adverse events were found between the groups. CONCLUSIONS: PMS implantation with sub-tenon injection of MMC was comparable in terms of efficacy and safety to traditional MMC delivery via soaked sponges. However, the injection group demonstrated a significantly higher success rate than the sponge group.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25001886
003      
CZ-PrNML
005      
20250123101952.0
007      
ta
008      
250117s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40123-024-01074-y $2 doi
035    __
$a (PubMed)39576486
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Majtanova, Nora $u Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Antolska 11, 851 07, Bratislava, Slovakia. nora.majtanova@gmail.com $1 https://orcid.org/0000000297942277
245    10
$a One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge / $c N. Majtanova, A. Takacova, V. Kurilova, L. Hejsek, J. Majtan, P. Kolar
520    9_
$a INTRODUCTION: This study was performed to compare the efficacy and safety of PreserFlo MicroShunt (PMS) implantation with mitomycin C (MMC) applied by sub-tenon injection versus conventional application by MMC-soaked sponges. METHODS: This retrospective, 1-year cohort study included 100 eyes of 100 patients with glaucoma who underwent PMS implantation with MMC (0.4 mg/ml) delivered either by sub-tenon injection (50 eyes) or via soaked sponges (50 eyes). The primary outcome measure at 1 year was intraocular pressure (IOP) reduction, with complete success defined as an IOP reduction of ≥ 20% and achieving a target IOP of ≤ 21 or 18 mmHg without the use of medication. Secondary outcomes, including corneal endothelial cell density (CECD) loss, the number of medications, and complications, were assessed and compared between the groups. RESULTS: Sustained reductions in mean IOP were observed in both groups over the 1-year follow-up, with no significant differences between the groups. The complete success rate, with a target IOP of ≤ 21 mmHg after 1 year, was 19.3% in the sponge group and 26.4% in the injection group. The qualified success rate was 59.0% and 87.4% in the sponge and injection groups, respectively. A longer survival rate was observed in the injection group than in the sponge group when IOP was below 21 mmHg. The mean CECD significantly decreased (P < 0.01) from baseline to each postoperative follow-up time point in both groups. At 1 year postoperatively, the percentage of total CECD loss was 8.1% in the sponge group and 8.0% in the injection group. However, no significant differences in mean CECD values, the number of medications, or adverse events were found between the groups. CONCLUSIONS: PMS implantation with sub-tenon injection of MMC was comparable in terms of efficacy and safety to traditional MMC delivery via soaked sponges. However, the injection group demonstrated a significantly higher success rate than the sponge group.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Takacova, Adriana $u Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Antolska 11, 851 07, Bratislava, Slovakia
700    1_
$a Kurilova, Veronika $u Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Antolska 11, 851 07, Bratislava, Slovakia $1 https://orcid.org/0000000187915761
700    1_
$a Hejsek, Libor $u Department of Ophthalmology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, 500 05, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000199738969 $7 mzk2007408327
700    1_
$a Majtan, Juraj $u Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska Cesta 21, 845 51, Bratislava, Slovakia. juraj.majtan@savba.sk $u Department of Microbiology, Faculty of Medicine, Slovak Medical University, 833 03, Bratislava, Slovakia. juraj.majtan@savba.sk $1 https://orcid.org/0000000272681584 $7 xx0106600
700    1_
$a Kolar, Petr $u Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Antolska 11, 851 07, Bratislava, Slovakia $1 https://orcid.org/0000000337094648 $7 xx0037722
773    0_
$w MED00210137 $t Ophthalmology and therapy $x 2193-8245 $g Roč. 14, č. 1 (2025), s. 153-167
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39576486 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101946 $b ABA008
999    __
$a ok $b bmc $g 2254417 $s 1237889
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 14 $c 1 $d 153-167 $e 20241122 $i 2193-8245 $m Ophthalmology and therapy $n Ophthalmol Ther $x MED00210137
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...